Skip to contentA
Acro Biomedical Co., Ltd.
A
ACBMAcro Biomedical Co., Ltd. Q1 2021 · 10-Q
Revenue$99.50K$99.50K−85.5% vs Q1 2020 Net Income-$59.49K-$59.49KN/M vs Q1 2020 EPS Diluted$0.00$0.00— vs Q1 2020 Gross Profit$29,500−81.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acro Biomedical Co., Ltd. · CIK 1622996 · Engraved from SEC EDGAR
Operating Cash Flow-$8,380N/M Margins · derivedGross margin29.6%+6.5 pt vs Q1 2020
Operating margin-57.3%−69.1 pt vs Q1 2020
Net margin-59.8%−71.6 pt vs Q1 2020
ended Mar 31, 2021 · filed May 24, 2021 · 54 d after period end